

## MAD2L1 Antibody (Center) Blocking peptide

Synthetic peptide Catalog # BP13837c

### **Specification**

## MAD2L1 Antibody (Center) Blocking peptide - Product Information

Primary Accession

**Q13257** 

# MAD2L1 Antibody (Center) Blocking peptide - Additional Information

**Gene ID 4085** 

#### **Other Names**

Mitotic spindle assembly checkpoint protein MAD2A, HsMAD2, Mitotic arrest deficient 2-like protein 1, MAD2-like protein 1, MAD2L1, MAD2

## Target/Specificity

The synthetic peptide sequence used to generate the antibody AP13837c was selected from the Center region of MAD2L1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## MAD2L1 Antibody (Center) Blocking peptide - Protein Information

Name MAD2L1

Synonyms MAD2

### **Function**

Component of the spindle-assembly checkpoint that prevents the onset of anaphase until all chromosomes are properly aligned at the metaphase plate (PubMed:<a href="http://www.uniprot.org/citations/29162720" target="\_blank">29162720</a>, PubMed:<a href="http://www.uniprot.org/citations/15024386" target="\_blank">15024386</a>). In the closed conformation (C-MAD2) forms a heterotetrameric complex with MAD1L1 at unattached kinetochores during prometaphase, the complex recruits open conformation molecules of MAD2L1 (O-MAD2) and then promotes the conversion of O-MAD2 to C-MAD2 (PubMed:<a href="http://www.uniprot.org/citations/29162720" target="\_blank">29162720</a>). Required for the execution of the mitotic checkpoint which monitors the process of kinetochore-spindle attachment and inhibits the activity of the anaphase promoting complex by sequestering CDC20



until all chromosomes are aligned at the metaphase plate (PubMed:<a href="http://www.uniprot.org/citations/10700282" target="\_blank">10700282</a>, PubMed:<a href="http://www.uniprot.org/citations/11804586" target="\_blank">11804586</a>, PubMed:<a href="http://www.uniprot.org/citations/15024386" target="\_blank">15024386</a>).

#### **Cellular Location**

Nucleus. Chromosome, centromere, kinetochore. Cytoplasm. Cytoplasm, cytoskeleton, spindle pole Note=Recruited by MAD1L1 to unattached kinetochores (Probable) Recruited to the nuclear pore complex by TPR during interphase Recruited to kinetochores in late prometaphase after BUB1, CENPF, BUB1B and CENPE. Kinetochore association requires the presence of NEK2 Kinetochore association is repressed by UBD. Sequestered to the cytoplasm upon interaction with isoform 3 of MAD1L1 (PubMed:19010891) {ECO:0000269|PubMed:19010891, ECO:0000305}

### MAD2L1 Antibody (Center) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

### Blocking Peptides

MAD2L1 Antibody (Center) Blocking peptide - Images

### MAD2L1 Antibody (Center) Blocking peptide - Background

MAD2L1 is a component of the mitotic spindle assemblycheckpoint that prevents the onset of anaphase until allchromosomes are properly aligned at the metaphase plate. MAD2L1 is related to the MAD2L2 gene located on chromosome 1. A MAD2pseudogene has been mapped to chromosome 14.

### MAD2L1 Antibody (Center) Blocking peptide - References

Guo, Y., et al. J. Med. Genet. 47(9):616-622(2010)Hewitt, L., et al. J. Cell Biol. 190(1):25-34(2010)Kalsi, G., et al. Hum. Mol. Genet. 19(12):2497-2506(2010)Wang, L., et al. Tumour Biol. 31(3):225-232(2010)Gladhaug, I.P., et al. Histopathology 56(3):345-355(2010)